Biocryst Pharmaceuticals

BCRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.238 B

$8.76 +0.92%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

$263.9M

#890 by earnings

Shares outstanding

255,535,105

Latest filing cover page

P/E ratio

8.5

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#28Beam TherapeuticsBEAM$2.61B
#29AlvotechALVO$2.30B
#30Biocryst PharmaceuticalsBCRX$2.24B
#31Adma BiologicsADMA$2.13B
#32Recursion PharmaceuticalsRXRX$2.13B

What if Biocryst Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$118,473.17

Per share 13,524× higher

Bitcoin $1.72T

$6,730.21

Per share 768× higher

Nvidia $5.48T

$21,444.64

Per share 2,448× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Biocryst Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.